All News
Addressing CV Risk in RA: Are we doing enough?
ORAL surveillance was a post-authorisation safety study of tofacitinib 5mg and 10mg versus TNF inhibitors, focusing on rates of adverse events, including MACE. A higher incidence of MACE was observed with the use of tofacitinib. Statins are recommended in patients with a history of atherosclerotic disease or 10 year predicted risk of MACE. But, how many patients with rheumatoid arthritis, at risk of MACE, are actually taking a statin?
Read ArticleCaoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Links:
📢Late-breaking #2003 🔑 Cappelli et al @jhrheumatology finds hip OA is NOT a significant risk factor for #ICI-IA 🔴#ICI-IA linked to lower mortality #ACR24 #ACRBest @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
TheDaoIndex KDAO2011 ( View Tweet)
Links:
Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24
TheDaoIndex KDAO2011 ( View Tweet)
Akhil Sood MD AkhilSoodMD ( View Tweet)
Mrinalini Dey DrMiniDey ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)